Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 609-534-4 | CAS number: 382-26-3
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
An oral toxicity study performed according to OECD 423 guideline,
a dermal toxicity study performed according to OECD 402 guideline and an
inhalation toxicity study performed according to OECD 403 guideline are
reported.
According to Regulation EC No. 1272/2008, the substance is classified as
following:
Acute oral toxicity Category 3
Acute Inhalation Toxicity Category 2.
The substance does not meet the classification criteria for Acute Dermal
Toxicity
Key value for chemical safety assessment
Acute toxicity: via oral route
Link to relevant study records
- Endpoint:
- acute toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 18 January 2005 to 16 March 2005
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Remarks:
- Guideline-conform study under GLP without deviations.
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 423 (Acute Oral toxicity - Acute Toxic Class Method)
- Version / remarks:
- 2001
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.1 tris (Acute Oral Toxicity - Acute Toxic Class Method)
- Version / remarks:
- 2004
- Deviations:
- no
- GLP compliance:
- yes (incl. QA statement)
- Test type:
- acute toxic class method
- Limit test:
- no
- Species:
- rat
- Strain:
- Wistar
- Sex:
- female
- Route of administration:
- oral: gavage
- Vehicle:
- polyethylene glycol
- Remarks:
- 300
- Doses:
- 2000 mg/kg, 300 mg/kg, 50 mg/kg
- No. of animals per sex per dose:
- 3 at dose of 2000 mg/kg
3 at dose of 300 mg/kg
6 at dose of 50 mg/kg - Control animals:
- no
- Key result
- Sex:
- female
- Dose descriptor:
- LD50
- Effect level:
- > 50 - < 300 mg/kg bw
- Based on:
- act. ingr.
- Interpretation of results:
- Category 3 based on GHS criteria
- Conclusions:
- The median lethal dose of Octafluoroisobutyl methyl ether after single oral administration to female rats, observed over a period of 14 days is:
50 mg / kg bw < LD50 (female rats) < 300 mg /kg bw. - Executive summary:
The study has been conducted in accordance with OECD 423 guideline Acute Oral toxicity - Acute Toxic Class Method.
Four groups, each of three female HanBri: WIST (SPF) rats, were treated with Octafluoroisobutyl Methyl Ether by oral gavage administration at a dosage of 2000 mg/kg, 300 mg/kg, 50 mg/kg body weight.
The following animals were treated and percentage of mortality was observed:
3 females treated at 2000 mg/kg
100 %
3 females treated at 300 mg/kg
100 %
6 females treated at 50 mg/kg
0 %
All three 2000 mg/kg treated animals died within five and a half hours after treatment. All three 300 mg/kg treated animals were found dead on test day 2.
Sightly ruffled fur was observed in all 2000 mg/kg treated animals from the 30 -minute reading to the 1- or 2 -hour reading and sligh to moderate ruffled fur persistent in one animal up to the 5 -hour reading. Hunched posture was noted in all three animlas of this group at the 30 -minute reading and persistent up to the 1 or 3 -hour observation in two animals. Slight to marked sedation was observed in all animals from the 30 -minute reading to the 1 -, 2 - or 5 -hour reading, respectively. Deep respiration was observed in one animal at the 3 -hour reading and was still noted at the 5 -hour examination. Ventral recumbency was seen in two animals one hour before death occurred.
In all animals treated with 300 mg/kg slightly ruffled fur and hunched posture was noted from the 1 -hour to the 5 -hour examination. Feces containing mucus was noted in two animals of the second-treated group at the 2 -hour or 3 -hour reading and persistent up to the 5 -hour observation in one animal. Hypothermia by hand-touch at the 5 -hour examination was noted in the same animals. All three animals in this group appeared slightly sedated at the 5 -hour observation.
The animals treated with 50mg/kg bw did not show any clinical signs.
The body weight of the animals was within the range commonly recorded for this strain and age.
In all three 2000 mg/kg bw trated animals, liquid contents were found in the stomach, duodenum, jejunum and ileum and additionally in the caecum of two animals at the unscheduled necropsy after spontaneous death. Stomach containing liquid and distended with gas was observed at the unscheduled necropsy of all three 300mg/kg bw treated animals.
In conclusion the median lethal dose of Octafluoroisobutyl methyl ether after single oral administration to female rats, observed over a period of 14 days is:
50 mg / kg bw < LD50 (female rats) < 300 mg /kg bw.
Reference
Mortality
All three 2000mg/kg treated animals died within five and half hours after treatment. All three 300 mg/kg treated animals were founded dead on test day 2.
Clinical signs
Sightly ruffled fur was observed in all 2000 mg/kg treated animals from the 30 -minute reading to the 1- or 2 -hour reading and sligh to moderate ruffled fur persistent in one animal up to the 5 -hour reading. Hunched posture was noted in all three animlas of this group at the 30 -minute reading and persistent up to the 1 or 3 -hour observation in two animals. Slight to marked sedation was observed in all animals from the 30 -minute reading to the 1 -, 2 - or 5 -hour reading, respectively. Deep respiration was observed in one animal at the 3 -hour reading and was still noted at the 5 -hour examination. Ventral recumbency was seen in two animals one hour before death occurred.
In all animals treated with 300 mg/kg slightly ruffled fur and hunched posture was noted from the 1 -hour to the 5 -hour examination. Feces containing mucus was noted in two animals of the second-treated group at the 2 -hour or 3 -hour reading and persistent up to the 5 -hour observation in one animal. Hypothermia by hand-touch at the 5 -hour examination was noted in the same animals. All three animals in this group appeared slightly sedated at the 5 -hour observation.
The animals treated with 50mg/kg bw did not show any clinical signs.
Macroscopic findings
In all three 2000 mg/kg bw treated animals, liquid contents were found in the stomach, duodenum, jejunum and ileum and additionally in the caecum of two animals at the unscheduled necropsy after spontaneous death. Stomach containing liquid and distended with gas was observed at the unscheduled necropsy of all three 300mg/kg bw treated animals.
Endpoint conclusion
- Endpoint conclusion:
- adverse effect observed
- Dose descriptor:
- discriminating dose
- Value:
- 50 mg/kg bw
Acute toxicity: via inhalation route
Link to relevant study records
- Endpoint:
- acute toxicity: inhalation
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 19 March 2004 to 01 March 2005
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Remarks:
- Guideline-conform study under GLP without deviations.
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 403 (Acute Inhalation Toxicity)
- Version / remarks:
- 1981
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.2 (Acute Toxicity (Inhalation))
- Version / remarks:
- 1992
- Qualifier:
- according to guideline
- Guideline:
- EPA OPPTS 870.1300 (Acute inhalation toxicity)
- GLP compliance:
- yes (incl. QA statement)
- Test type:
- acute toxic class method
- Limit test:
- no
- Species:
- rat
- Strain:
- Wistar
- Sex:
- male/female
- Route of administration:
- inhalation: vapour
- Type of inhalation exposure:
- nose only
- Vehicle:
- air
- Analytical verification of test atmosphere concentrations:
- yes
- Remarks:
- Sampling of test atmosphere was performed 4 times during the inhalation exposure period of groups 1, 2, 3 and twice during the inhalation exposure period of group 4. Samples were analyzed by GC-MS.
- Duration of exposure:
- 4 h
- Concentrations:
- ca. 20 mg/L air (19.63 mg/L air)
ca. 2 mg/L air (2.197 mg/L air)
ca. 0.5 mg/L air (0.827 mg/L air)
ca. 0.2 mg/L air (0.178 mg/L air) - No. of animals per sex per dose:
- 10 (5 males + 5 females)
- Control animals:
- no
- Key result
- Sex:
- male/female
- Dose descriptor:
- LC50
- Effect level:
- 1.06 mg/L air
- Based on:
- act. ingr.
- 95% CL:
- > 0.64 - < 2.42
- Exp. duration:
- 4 h
- Interpretation of results:
- Category 2 based on GHS criteria
- Conclusions:
- The LC50 of 2-[difluoro(methoxy)methyl]-1,1,1,3,3,3-hexafluoropropane for acute inhalation toxicity (4h) in male and female rats observed for a period of 15 days was estimated to be:
LC50 = 1.06 mg/L air (0.64 - 2.42 mg/L air) - Executive summary:
The study has been conducted in accordance with OECD 403 guideline Acute Inhalation toxicity.
Four groups, each of five male and five female Wistar rats, were treated with nebulized Octafluoroisobutyl Methyl Ether at concentration of ca. 20 mg/L air, ca. 2 mg/L air, ca. 0.5 mg/L air mg/kg, ca. 0.2 mg/L air.
Calculation of the saturation point of the test item, revealed that virtually all of the test atmosphere was a vapour at any of the atmosphere concentrations tested in the present study.
The following groups were treated and percentage of mortality was observed:
Analytical Concentration
Mortality
(Both genders)
Mortality (Males Only)
Mortality (Females Only)
GROUP 1
0.178 mg/L air
0 %
0 %
0 %
GROUP 2
0.827 mg/L air
10 %
20 %
0 %
GROUP 3
2.197 mg/L air
100 %
100 %
100 %
GROUP 4
19.63 mg/L air
100 %
100 %
100 %
The no toxic effect level was set at 0.178 mg/L air, as there were no deaths, no clinical signs and no macroscopic pathology findings at this atmosphere concentration. One of ten animals died in Group 2 (0.827 mg/L air) and all animals died in Group 3 (2.197 mg/L air) and 4 (19.63 mg/L air). Clinical signs were only seen in decedent animals and comprised effects on breathing in Groups 2, 3 and 4, in addition to decreased spontaneous activity, ventral recumbency and ruffled fur in Group 3, and somnolence in Group 4. Mortality and clinical signs were attributed to treatment with the test item. Whether or not transient retardation in body weight gain or transient body weight losses in several male and female survivoers of Groups 1 and 2 were attributable to the treatment remained unclear. Necropsy revealed dark red or reddish discoloration of the lungs in the one decedent animal of Group 2 and all animals of Groups 3 and 4, in addition to an isolated grey white focus of 2 mm diameter in the lungs of the one affected animal of Group 2.A relationship of the finding of lung discoloration to treatment remained unclear. The single incidence of an isolated grey white focus was not attributed to the treatment. The was no indication of relevant sex-related differences in toxicity of the test item.
The LC50 of 2-[difluoro(methoxy)methyl]-1,1,1,3,3,3-hexafluoropropane for acute inhalation toxicity (4h) in male and female rats observed for a period of 15 days was estimated to be:
LC50 = 1.06 mg/L air (0.64 - 2.42 mg/L air)
Reference
For calculation of the LC50 estimates, mean chemically determined concentrations of the test item in the test atmosphere samples of Group 1 (0.178 mg/L air), Group 2 (0.827 mg/L air), Group 3 (2.197 mg/L air) were used. The no toxic effect level was set at 0.178 mg/L air, as there were no deaths, no clinical signs and no macroscopic pathology findings at this atmosphere concentration.
One of ten animals died in Group 2 (0.827 mg/L air) and all animals died in Group 3 (2.197 mg/L air) and 4 (19.63 mg/L air).
Clinical signs were only seen in decedent animals and comprised effects on breathing in Groups 2, 3 and 4, in addition to decreased spontaneous activity, ventral recumbency and ruffled fur in Group 3, and somnolence in Group 4.
Mortality and clinical signs were attributed to treatment with the test item. Whether or not transient retardation in body weight gain or transient body weight losses in several male and female survivoers of Groups 1 and 2 were attributable to the treatment remained unclear.
Necropsy revealed dark red or reddish discoloration of the lungs in the one decedent animal of Group 2 and all animals of Groups 3 and 4, in addition to an isolated grey white focus of 2 mm diameter in the lungs of the one affected animal of Group 2.A relationship of the finding of lung discoloration to treatment remained unclear. The single incidence of an isolated grey white focus was not attributed to the treatment.
There was no indication of relevant sex-related differences in toxicity of the test item.
Endpoint conclusion
- Endpoint conclusion:
- adverse effect observed
- Dose descriptor:
- LC50
- Value:
- 1 060 mg/m³ air
Acute toxicity: via dermal route
Link to relevant study records
- Endpoint:
- acute toxicity: dermal
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 19 January 2005 to 1 March 2005
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Remarks:
- Guideline-conform study under GLP without deviations.
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 402 (Acute Dermal Toxicity)
- Version / remarks:
- 1987
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.3 (Acute Toxicity (Dermal))
- Version / remarks:
- 1992
- Deviations:
- no
- GLP compliance:
- yes (incl. QA statement)
- Test type:
- standard acute method
- Limit test:
- yes
- Species:
- rat
- Strain:
- Wistar
- Sex:
- male/female
- Type of coverage:
- semiocclusive
- Vehicle:
- unchanged (no vehicle)
- Duration of exposure:
- 24 hours
- Doses:
- 2000 mg/kg bw
- No. of animals per sex per dose:
- 10 (5 males and 5 females)
- Control animals:
- no
- Key result
- Sex:
- male/female
- Dose descriptor:
- LD50
- Effect level:
- > 2 000 mg/kg bw
- Based on:
- act. ingr.
- Interpretation of results:
- GHS criteria not met
- Conclusions:
- The median lethal dose of Octafluoroisobutyl methyl ether after single dermal administration to rats of both sexsx, observed over a period of 14 days is: LD50 (rat) > 2000 mg/kg bw.
- Executive summary:
The study has been conducted in accordance with OECD 402 guideline - Acute Dermal toxicity.
Five males and females HanBri: WIST (SPF) rats were treated with Octafluoroisobutyl methyl ether at 2000 mg/kg bw by dermal application.
No deaths occurred during the study.
Exophtlamus was noted in one male animal from test day 13 to the end of the observation period. No clinical signs were observed during the course of the study in all other animals.
The body weight of the animals was within the range commonly recorded for this strain and age.
No macroscopic findings were observed at necropsy.
In conclusion the median lethal dose of Octafluoroisobutyl methyl ether after single dermal administration to rats of both sexes, observed over a period of 14 days is: LD50 (rat) greater than 2000 mg/kg bw.
Reference
Mortality
No deaths occurred during the study.
Clinical / Local signs
Exophtlamus was noted in one male animal from test day 13 to the end of the observation period. No clinical signs were observed during the course of the study.
Body weights
The body weight of the animals was within the range commonly recorded for this strain and age.
Macroscopic findings
No macroscopic findings were observed at necropsy
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- discriminating dose
- Value:
- 2 000 mg/kg bw
Additional information
An oral toxicity study performed according to OECD guideline 423, a dermal toxicity study performed according to OECD guideline 402 and an inhalation toxicity study performed according to OECD 403 guideline are reported.
The median lethal dose of 2-[difluoro(methoxy)methyl]-1,1,1,3,3,3-hexafluoropropane after single oral administration to female rats, observed over a period of 14 days is:
50 mg / kg bw < LD50 (female rats) < 300 mg /kg bw.
The LC50 of 2-[difluoro(methoxy)methyl]-1,1,1,3,3,3-hexafluoropropane for acute inhalation toxicity (4h) in male and female rats observed for a period of 15 days was estimated to be:
LC50 = 1.06 mg/L air (0.64 - 2.42 mg/L air)
The median lethal dose of 2-[difluoro(methoxy)methyl]-1,1,1,3,3,3-hexafluoropropane ether after single dermal administration to rats of both sexes, observed over a period of 14 days is:
LD50 (rat) > 2000 mg/kg bw.
Justification for selection of acute toxicity – oral endpoint
Available study, conducted under GLP and according to recognized
international standard guideline.
Justification for selection of acute toxicity – inhalation endpoint
Available study, conducted under GLP and according to recognized
international standard guideline.
Justification for selection of acute toxicity – dermal endpoint
Available study, conducted under GLP and according to recognized
international standard guideline.
Justification for classification or non-classification
2-[difluoro(methoxy)methyl]-1,1,1,3,3,3-hexafluoropropane meets the GHS classification criteria both for acute oral and inhalation toxicity, therefore the substance, according to Regulation EC No. 1272/2008, is classified as following:
Acute oral toxicity Category 3
Acute Inhalation Toxicity Category 2.
The substance does not meet the classification criteria for Acute Dermal Toxicity.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.